COHERUS ONCOLOGY INC (CHRS)
Health Care · Biotechnology / Immuno-Oncology · NASDAQ
A specialized immuno-oncology company driving growth through its FDA-approved PD-1 inhibitor LOQTORZI and a clinical-stage pipeline targeting immune resistance in solid tumors.
What COHERUS ONCOLOGY INC does
Coherus Oncology is a commercial-stage pharmaceutical company focused on the development and commercialization of innovative immuno-oncology medicines. Its lead commercial product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody approved for the treatment of nasopharyngeal carcinoma, alongside a pipeline of clinical-stage candidates designed to target immune resistance in various solid tumors. The company recently transitioned from a diversified biosimilar business to a pure-play oncology focus.
Recent developments
In Q2 2026, the company reported LOQTORZI revenue of $13.6 million, reflecting a 15% increase sequentially. Clinical programs continue to progress with enrollment complete for the casdozokitug Phase 2 study in HCC, with initial data readouts for both casdozokitug and tagmokitug expected in the second half of 2026.
From COHERUS ONCOLOGY INC's filing of 2026-08-05.
Themes: immuno-oncology, PD-1 inhibitor, solid tumors, cancer drug development, Treg depletion, IL-27 inhibition
Fundamentals
- Price$1.00 as of 2026-10-20 close
- Market cap$155M as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-44.1% 2025-10-20 close $1.79 → 2026-10-20 close $1.00
- P/En/a negative earnings
- ROE+275.4% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.50 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CHRS compares in its sector
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$32M | -$21M | -$0.13 | -$62M† |
| Q1 FY2026 2026-03-31 | -$36M | -$38M | -$0.28 | -$58M |
| Q4 FY2025 2025-12-31 | -$46M† | -$38M† | -$0.34† | -$20M† |
| Q3 FY2025 2025-09-30 | -$44M | -$36M | -$0.31 | -$46M† |
| Q2 FY2025 2025-06-30 | -$45M | $298M | $2.57 | -$47M† |
| Q1 FY2025 2025-03-31 | -$45M | -$57M | $2.57 | -$26M |
| Q4 FY2024 2024-12-31 | -$45M† | -$51M† | -$0.44† | $29M† |
| Q3 FY2024 2024-09-30 | -$47M | -$11M | -$0.09 | -$62M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$83M
- Short-term investments$22M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How COHERUS ONCOLOGY INC looks technically
COHERUS ONCOLOGY INC (CHRS) is trading 35.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 77 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 61.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 35.6% below its 200-day average, the long-term trend line — a long-term downtrend | -35.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.23 | $1.23 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.55 | $1.55 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 1.36. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 77 trading days ago — a "death cross", a bearish long-term signal | 77 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 23.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 38.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($0.9414 to $1.21) — its "stochastic" reading is 22 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 21.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 26 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.62 | $2.62 |
|---|---|---|
| From the 52-week high | it is 61.8% below its 52-week high (its highest price of the past year) | -61.8% |
| Above the 52-week low | it is 6.2% above its 52-week low (its lowest price of the past year) | +6.2% |
| Below the 52-week high | it is 61.8% below its highest point of the past year | 61.8% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $38.10 (set on 2015-07-22) | $38.10 |
| Given back of the 52-week move | over the past year its closes ranged ($0.9587 to $2.51), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.92 to $1.97. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.7% |
| From the all-time high | it is 97.4% below its all-time high | -97.4% |
| Nearest price level | it is trading 4.3% above a support level at $0.9575 — a price it turned at twice since 2024-11-07, most recently on 2025-07-14. Since 2024-10-21 it has 3 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.3% |
| All-time low | its lowest closing price on record is $0.6603 (set on 2024-11-05) | $0.6603 |
| Above the all-time low | it is 51.4% above its all-time low | +51.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 74% of it) | 74th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0797 between its high and its low — about 8.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0797 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.94 and $1.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.94 – $1.09 – $1.25 |
| Typical daily range (% of price) | its price moves about 8.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.0% |
| Stretch from the 200-day average | it is trading 6.9 daily ranges below its 200-day average price (35.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Gap filled | a 2.9% gap up opened on 2026-10-13 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.9 percentage points (the stock lost 25.9% while the market gained 1.0%) | -26.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 33.2 percentage points (the stock lost 29.6% while the market gained 3.6%) | -33.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 58.3 percentage points (the stock lost 49.7% while the market gained 8.5%) | -58.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 58.7 percentage points (the stock lost 44.1% while the market gained 14.6%) | -58.7% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -25.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.64 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -39.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.23 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -18.6% |
Price levels it has turned at before
CHRS last closed at $1.00 on 2026-10-20. Since 2024-10-21 it has turned at 3 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.9575 | Support | 4.3% below the last close | turned there twice · 2024-11-07 to 2025-07-14 |
| $1.15 | Resistance | 15.3% above the last close | turned there three times · 2025-04-23 to 2025-12-03 |
| $0.7377 | Support | 26.2% below the last close | turned there twice · 2025-05-23 to 2025-06-03 |
| $1.26 | Resistance | 26.5% above the last close | turned there twice · 2025-08-25 to 2025-12-29 |
| $0.7067 | Support | 29.3% below the last close | turned there three times · 2024-11-15 to 2025-06-23 |
| $1.38 | Resistance | 37.9% above the last close | turned there five times · 2025-01-30 to 2026-07-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $1.36.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.10 and $1.25 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $0.974.
This reading has stood for 1 trading day, since 2026-10-20.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$7.75 range $4.00 – $10.00; median $8.50
Analyst estimates, as of 2026-10-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CHRS
- Consensus EPS estimate-$0.21 next reporting period, as of 2026-10-21
- Estimate change, 30 days$0.00 from -$0.21, on 2026-09-16, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Limited history of profitability and reliance on a single marketed product.","Significant expenses and financial risks associated with the clinical development of novel oncology pipeline candidates.","Dependency on partnerships for product development and commercial rights, such as with Junshi Biosciences."]
What changed in the latest 10-Q
AI-assisted comparison of CHRS's 10-Q filed 2026-08-05 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-05) adds mention of Zumutor Biologics evaluating ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with toripalimab (clinicaltrials.gov identifier# NCT06451497), including that the study will enroll patients with advanced solid tumors including colorectal, head and neck, non-small cell lung cancer, clear cell renal cell carcinoma and urothelial cancers.
- Removed:
- Older filing (filed 2026-05-11) contains mention of STORM Therapeutics, Ltd. evaluating its METTL3 inhibitor STC-15 in combination with LOQTORZI in a Phase 1b/2 study (clinicaltrials.gov identifier# NCT06975293) for the treatment of non-small cell lung cancer and head and neck squamous cell carcinoma, with plans for melanoma and endometrial cancer.
- Reworded:
- In the strategy sentence: older filing states "advancing the development of our two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships"; newer filing states "advancing the development of our two pipeline candidates in combination with LOQTORZI and/or with other novel agents, and through strategic partnerships".
- In the LOQTORZI section: older filing writes "Junshi Biosciences is currently enrolling in a multiregional Phase 3 clinical study evaluating the treatment of LOQTORZI with its investigational anti-BTLA antibody in LS-SCLC"; newer filing expands "LS-SCLC" to "Limited-Stage Small Cell Lung Cancer ("LS-SCLC")".
- In the LOQTORZI section: older filing describes the Apotex agreement as "we entered into a license Agreement with Apotex, Inc. ("Apotex"), pursuant to which, we granted to Apotex an exclusive license under our rights to toripalimab to commercialize toripalimab within Canada ("Canada License Agreement")"; newer filing states "we entered into the Canada License Agreement with Apotex."
- In the Tagmokitug description: older filing says tagmokitug is designed to cause depletion of "intra-tumoral Treg cells"; newer filing says depletion of "CCR8+ Treg cells".
- In the Tagmokitug description: older filing abbreviates "Antibody-Dependent Cell-mediated Cytotoxicity ("ADCC"), Antibody-Dependent Cellular Phagocytosis or ("ADCP")"; newer filing writes "Antibody-Dependent Cell-mediated Cytotoxicity ("ADCC"), Antibody-Dependent Cellular Phagocytosis or ("ADCP") or both".
- In the Janssen clinical supply agreement paragraph: older filing ends with "Janssen and us each retain all commercial rights to our respective compounds, including as mono"; newer filing ends with "Jansse" (text appears truncated in both filings at different points).
- Notes:
- The newer filing text ends mid-sentence with 'Jansse' and the older filing text ends mid-sentence with 'including as mono', so the final sentences in both versions are truncated and cannot be fully compared.
Risk Factors
- Added:
- In the newer filing (filed 2026-08-05), the phrase 'as of June 30, 2026, we had an accumulated deficit of $1.4 billion' reflects the updated date and quarter-end.
- In the newer filing (filed 2026-08-05), the cash, cash equivalents and marketable securities figure was updated to '$105.3 million' as of June 30, 2026.
- In the newer filing (filed 2026-08-05), the phrase 'we have agreed to pay up to $90.0 million' includes 'we have agreed' instead of 'have agreed'.
- In the newer filing (filed 2026-08-05), the sentence 'The UDENYCA Sale has been consummated' is worded as 'particularly now that the UDENYCA Sale has been consummated' instead of 'particularly now that the UDENYCA Sale was consummated'.
- Removed:
- In the older filing (filed 2026-05-11), the phrase 'as of March 31, 2026, we had an accumulated deficit of $1.4 billion' reflected the prior quarter-end date.
- In the older filing (filed 2026-05-11), the cash, cash equivalents and marketable securities figure was '$167.0 million' as of March 31, 2026.
- In the older filing (filed 2026-05-11), the phrase 'have agreed to pay up to $90.0 million' appeared without 'we have agreed'.
- In the older filing (filed 2026-05-11), the sentence 'particularly now that the UDENYCA Sale was consummated' used the word 'was' instead of 'has been'.
- Reworded:
- The date of the accumulated deficit disclosure changed from 'March 31, 2026' (older filing, filed 2026-05-11) to 'June 30, 2026' (newer filing, filed 2026-08-05).
- The cash, cash equivalents and marketable securities amount changed from '$167.0 million' (older filing, filed 2026-05-11) to '$105.3 million' (newer filing, filed 2026-08-05).
- The phrase 'have agreed to pay' in the older filing (filed 2026-05-11) was changed to 'we have agreed to pay' in the newer filing (filed 2026-08-05).
- The word 'was consummated' in the older filing (filed 2026-05-11) was changed to 'has been consummated' in the newer filing (filed 2026-08-05).
- Notes:
- The source texts are truncated mid-sentence in both filings, ending at 'including but not limited to' in the newer filing and 'including but not limited' in the older filing, so changes after that point cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CHRS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CHRS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 15,305,814
- Reported value $21,428,140
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CHRS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CHRS had 23,337,539 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
CHRS had 15.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.53 days to cover at the same settlement.
- Reported short interest (shares) 23,337,539
- Short interest (% of shares outstanding) 15.1%
- Prior settlement (shares) 22,848,985
- Reported change 2.14%
- Days to cover (reported) 12.53
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
- Roche (RHHBY)
- Regeneron (REGN)
- BeiGene (BGNE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CHRS vs…
COHERUS ONCOLOGY INC is found in…
CHRS ranks in…
Frequently asked questions
What does COHERUS ONCOLOGY INC (CHRS) do?
Coherus Oncology is a commercial-stage pharmaceutical company focused on the development and commercialization of innovative immuno-oncology medicines. Its lead commercial product is LOQTORZI (toripalimab-tpzi), an anti-PD-1 antibody approved for the treatment of nasopharyngeal carcinoma, alongside a pipeline of clinical-stage candidates designed to target immune resistance in various solid tumors.
What sector is COHERUS ONCOLOGY INC (CHRS) in?
COHERUS ONCOLOGY INC (CHRS) is classified in the Health Care sector. Its industry is Biotechnology / Immuno-Oncology. It trades on NASDAQ.
Who are COHERUS ONCOLOGY INC's (CHRS) competitors?
Notable peers of COHERUS ONCOLOGY INC (CHRS) include Merck, Bristol Myers Squibb, AstraZeneca, Roche and Regeneron. This peer set is informational only — not financial advice.
Is COHERUS ONCOLOGY INC (CHRS) overbought or oversold right now?
COHERUS ONCOLOGY INC (CHRS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CHRS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.